May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Inhibition Of VEGF–Induced Endothelial Cell Poliferation And Differentiation By Steroidal And Non–steroidal Cox Inhibitors With Variable Cox–1/Cox–2 Selectivity
Author Affiliations & Notes
  • R. Yang
    Ophthalmology & Visual Sciences, Vanderbilt University, Nashville, TN
  • G.W. McCollum
    Ophthalmology & Visual Sciences, Vanderbilt University, Nashville, TN
  • D.P. Bingaman
    Alcon Research, Ltd., Ft Worth, TX
  • J.S. Penn
    Ophthalmology & Visual Sciences, Vanderbilt University, Nashville, TN
  • Footnotes
    Commercial Relationships  R. Yang, None; G.W. McCollum, None; D.P. Bingaman, Alcon Research, Ltd. E; J.S. Penn, Alcon Research, Ltd F, C.
  • Footnotes
    Support  EY07533
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 1914. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R. Yang, G.W. McCollum, D.P. Bingaman, J.S. Penn; Inhibition Of VEGF–Induced Endothelial Cell Poliferation And Differentiation By Steroidal And Non–steroidal Cox Inhibitors With Variable Cox–1/Cox–2 Selectivity . Invest. Ophthalmol. Vis. Sci. 2004;45(13):1914.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Endothelial cell proliferation and differentiation are critical components of angiogenesis. Inhibition of VEGF–induced bovine retinal microvascular endothelial cell (BRMEC) proliferation and tube formation (differentiation) in vitro was tested with the following series of steroidal and non–steroidal cyclooxygenase (COX) inhibitors with varied COX–1/COX–2 selectivity: the deaminated derivative of nepafenac, celocoxib, rofecoxib, diclofenac salt, ketorolac tromethamine salt, NS398, SC560 and dexamethasone. The PKC–beta inhibitor, LY333531, and the active metabolite of anecortave acetate were used as known active controls. Methods: BRMEC were grown on 96–well plates coated with fibronectin/hyaluronic acid. Growth medium was added for 2d followed by serum free medium overnight. Test medium containing 25 ng/ml VEGF, 0.1%DMSO and COX inhibitor at concentrations ranging from 0.01 to 10 mM was added for 24 hr. BRMEC proliferation was assayed using a modified MTT assay. For tube formation, BRMEC were grown on 6–well plates, within a Vitrogen 100 growth matrix sandwich and incubated in growth medium for 2d. The medium was replaced with 0.5% FBS plus 25 ng/ml VEGF with and without COX inhibitor and 0.1% DMSO. The mean tube length of each experimental group was digitally analyzed after 48hr in the experimental medium. Results: All test compounds except dexamethasone demonstrated inhibition of VEGF–induced BRMEC proliferation ranging from 42%–100%. The deaminated derivative of nepafenac, the active metabolite of anecortave acetate and celecoxib appeared to be the most potent. All test compounds showed inhibition of tube formation ranging from 28%–100%, with the deaminated derivative of nepafenac, celecoxib, rofecoxib, diclofenac and ketorolac being the most effective. Conclusions: Rofecoxib and celecoxib are COX–2 selective NSAIDs, while the nepafenac derivative and diclofenac are non–selective. Yet, the abilities of these compounds to inhibit endothelial cell proliferation and differentiation are comparable. Thus, it appears that COX selectivity is not a determining factor in the angiostatic activity demonstrated by these compounds.

Keywords: retinal neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×